Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Vircell S.L.

Vircell is a biotechnology company specializing in the development and production of ready-to-use reagents for the di... read more Featured Products: More products

Download Mobile App





Vircell Announces Immediate Release of COVID-19 Research Kit

By LabMedica International staff writers
Posted on 05 Mar 2020
An all-out R&D program carried out by the biotechnology company Vircell (Granada, Spain) has resulted in a PCR-based test for the detection of COVID-19.

A novel coronavirus of zoonotic origin, the 2019-nCoV virus (the causative agent of COVID-19 disease) was recently identified in patients with acute respiratory disease. More...
This virus is genetically similar to SARS coronavirus and bat SARS-like coronaviruses. The outbreak was initially detected in Wuhan, a major city in China, but has subsequently been detected in other provinces of China as well as in major outbreaks in several other countries in Asia (South Korea, Thailand, Japan) and Europe (Italy). At this time nearly 80,000 cases of the disease have been confirmed with close to 3,000 fatalities.

Signs of infection are highly non-specific and these include respiratory symptoms, fever, cough, dyspnea, and viral pneumonia. Currently, experts estimate that only a small percentage of coronavirus cases have actually been diagnosed clinically. Therefore, diagnostic tests specific for this infection are urgently needed for confirming suspected cases, screening patients, and conducting virus surveillance.

In response to the potential pandemic spread of the virus, Vircell rapidly developed a product for detection of COVID-19 that is available right now for research use.

The new product generates fast and reliable results in 90 minutes and is suitable for use in any qPCR thermal cycler with (FAM/HEX) detection. It is a double-target assay, specific for COVID-19 and other coronaviruses related to SARS. The assay kit contains two lyophilized master mixes for virus detection and confirmation, as suggested by international guidelines.

The assay does not show cross reactions with other common human respiratory CoVs or MERS and includes an internal amplification control in each master mix.

Vircell, which has always been concerned and committed to respiratory infectious diseases in China, has now made a tremendous R&D effort to develop this novel product in order to contribute as much as possible to understanding and containing this highly contagious disease.

Related Links:
Vircell


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.